{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:14:01Z","timestamp":1792588441366,"version":"4.5.0"},"reference-count":102,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,3,24]],"date-time":"2019-03-24T00:00:00Z","timestamp":1553385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Excessive complement activation is involved in the pathogenesis of many diseases and the kidney is an organ with particular susceptibility to complement-mediated injury. Apart from paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), there are several other diseases with clear evidence of complement activation affecting both maternal and fetal kidneys during pregnancy and causing long-term adverse outcomes. Several novel drugs have been recently developed for blocking the complement cascade, including purified plasma proteins, new monoclonal antibodies, recombinant proteins, small molecules, and small interfering RNA agents. Eculizumab, the humanized monoclonal IgG2\/4-antibody targeting C5 was approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treatment of two rare diseases: PNH in 2007 and aHUS in 2011. There is an increasing number of publications of successful use of eculizumab for off-label indications, e.g., in pregnant women with antiphospholipid syndrome, sickle-cell anemia, and HELLP syndrome. These severe diseases are associated with both high maternal and fetal morbidity and mortality rate and substantial prematurity. Eculizumab has considerably improved overall outcome of patients with PNH and aHUS, enabling safe pregnancy for many women. Prolongation of pregnancy and the use of eculizumab, even for only a few weeks, may protect not only maternal renal function, but also alleviate acute and long-term renal consequences of prematurity in offspring.<\/jats:p>","DOI":"10.3390\/jcm8030407","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T06:56:52Z","timestamp":1553497012000},"page":"407","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The Extended Use of Eculizumab in Pregnancy and Complement Activation\u2013Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys\u2014The Future Is Now?"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-1698","authenticated-orcid":false,"given":"Vedran","family":"Stefanovic","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Helsinki University and Helsinki University Hospital, Haartmaninkatu 2, 00290 Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.2215\/CJN.09450912","article-title":"Obstetric nephrology: Pregnancy and the kidney\u2014Inextricably linked","volume":"7","author":"Agust","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molimm.2015.02.030","article-title":"The complement system and adverse pregnancy outcomes","volume":"67","author":"Regal","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5301\/jn.5000013","article-title":"Acute kidney injury in pregnancy: A clinical challenge","volume":"25","author":"Machado","year":"2012","journal-title":"J. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40348-016-0068-0","article-title":"Renal consequences of preterm birth","volume":"4","author":"Stritzke","year":"2017","journal-title":"Mol. Cell. Pediatr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.siny.2015.12.007","article-title":"Global burden of prematurity","volume":"21","author":"Harrison","year":"2016","journal-title":"Semin. Fetal Neonatal Med."},{"key":"ref_6","first-page":"103","article-title":"Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: Review and recommendations for management of the pregnant and nonpregnant patient","volume":"30","author":"Ray","year":"2000","journal-title":"Haemostasis"},{"key":"ref_7","first-page":"662","article-title":"The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy","volume":"91","author":"Dashe","year":"1998","journal-title":"Obstet. Gynecol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J. Clin. Invest."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1177\/0961203314546022","article-title":"Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies","volume":"23","author":"Willis","year":"2014","journal-title":"Lupus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e6338","DOI":"10.1097\/MD.0000000000006338","article-title":"Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report","volume":"96","author":"Gustavsen","year":"2017","journal-title":"Medicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e12584","DOI":"10.1097\/MD.0000000000012584","article-title":"Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: A case report","volume":"97","author":"Canti","year":"2018","journal-title":"Medicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.3324\/haematol.2017.174201","article-title":"In vitro evidence of complement activation in patients with sickle cell disease","volume":"102","author":"Gavriilaki","year":"2017","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/bjh.13884","article-title":"Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab","volume":"175","author":"Chonat","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2018-99-118396","article-title":"Use of Eculizumab for the Treatment of Hyperhaemolysis in Pregnancy in Sickle Cell Disease: A Case Report","volume":"132","author":"Kirui","year":"2018","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2016.03.014","article-title":"Are there any additional mechanisms for haemolysis in HELLP syndrome?","volume":"142","author":"Sabau","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.exphem.2016.01.005","article-title":"Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome","volume":"44","author":"Vaught","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/jpm-2014-0118","article-title":"Neonatal outcome in pregnant patients with antiphospholipid syndrome","volume":"43","author":"Jeremic","year":"2015","journal-title":"J. Perinat. Med."},{"key":"ref_19","first-page":"525","article-title":"Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: The PREGNANTS study","volume":"216","author":"Saccone","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ijgo.12511","article-title":"Antiphospholipid syndrome characteristics and adverse pregnancy outcomes after 20 weeks of pregnancy","volume":"142","author":"Blickstein","year":"2018","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_21","first-page":"323","article-title":"[Pregnancy outcome in 54 patients with antiphospholipid syndrome: A retrospective clinical study]","volume":"46","author":"Zheng","year":"2014","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1875-9572(09)60052-8","article-title":"Neonatal and Pregnancy Outcome in Primary Antiphospholipid Syndrome: A 10-year Experience in One Medical Center","volume":"50","author":"Chou","year":"2009","journal-title":"Pediatr. Neonatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Muganyizi, P.S., and Kidanto, H. (2013). Sickle Cell Disease in Pregnancy: Trend and Pregnancy Outcomes at a Tertiary Hospital in Tanzania. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056541"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Elenga, N., Adeline, A., Balcaen, J., Vaz, T., Calvez, M., Terraz, A., Accrombessi, L., and Carles, G. (2016). Pregnancy in Sickle Cell Disease Is a Very High-Risk Situation: An Observational Study. Obstet. Gynecol. Int., 069054.","DOI":"10.1155\/2016\/9069054"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Alkhunaizi, A.M., Al-Khatti, A.A., and Alkhunaizi, M.A. (2018). Prevalence of Microalbuminuria in Adult Patients with Sickle Cell Disease in Eastern Saudi Arabia. Int. J. Nephrol., 5015764.","DOI":"10.1155\/2018\/5015764"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2014-11-607317","article-title":"Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: Systematic review and meta-analysis","volume":"125","author":"Meeks","year":"2015","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.critrevonc.2015.11.018","article-title":"Pregnancy and sickle cell disease: A review of the current literature","volume":"98","author":"Boga","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_28","first-page":"130","article-title":"Complement activation in asymptomatic patients with sickle cell anaemia","volume":"36","author":"Wilson","year":"1979","journal-title":"Clin. Exp. Immunol."},{"key":"ref_29","first-page":"57","article-title":"Plasma haemoglobin and complement activation in sickle cell disease","volume":"6","author":"DeCeulaer","year":"1981","journal-title":"J. Clin. Lab. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4269\/ajtmh.1993.49.799","article-title":"Increased in vivo activation of neutrophils and complement in sickle cell disease","volume":"49","author":"Mohamed","year":"1993","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.transci.2016.04.008","article-title":"The role of complement activation in thrombosis and hemolytic anemias","volume":"54","author":"Chapin","year":"2016","journal-title":"Transfus. Apher. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum. Mutat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/M18-1161","article-title":"Clinical Outcomes Associated With Sickle Cell Trait: A Systematic Review","volume":"169","author":"Naik","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3324\/haematol.2016.153791","article-title":"Risk factors for mortality in adult patients with sickle cell disease: A meta-analysis of studies in North America and Europe","volume":"102","author":"Maitra","year":"2017","journal-title":"Haematologica"},{"key":"ref_35","first-page":"467","article-title":"Pre-eclampsia: Pathophysiology, diagnosis, and management","volume":"7","author":"Uzan","year":"2011","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"385.e1","DOI":"10.1016\/j.ajog.2007.10.793","article-title":"Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia","volume":"198","author":"Lynch","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ki.2010.393","article-title":"Targeted inhibition of complement activation prevents features of preeclampsia in mice","volume":"79","author":"Qing","year":"2011","journal-title":"Kidney Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/jcmm.13466","article-title":"Complement 5a-mediated trophoblasts dysfunction is involved in the development of pre-eclampsia","volume":"22","author":"Ma","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e99128","DOI":"10.1172\/jci.insight.99128","article-title":"Germline mutations in the alternative pathway of complement predispose to HELLP syndrome","volume":"22","author":"Vaught","year":"2018","journal-title":"JCI Insight."},{"key":"ref_40","unstructured":"Noris, M., Bresin, E., Mele, C., and Remuzzi, G. (1993). Genetic atypical hemolytic-uremic syndrome. GeneReviews(R), University of Washington."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000082648","article-title":"Perinatal outcomes in severe preeclampsia-eclampsia with and without HELLP syndrome","volume":"59","author":"Gul","year":"2005","journal-title":"Gynecol. Obstet. Invest."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1515\/JPM.2003.027","article-title":"The HELLP-syndrome; maternal-fetal outcome and follow up of infants","volume":"31","author":"Roelofsen","year":"2003","journal-title":"J. Perinat. Med."},{"key":"ref_43","first-page":"213","article-title":"Factors affecting maternal and perinatal outcomes in HELLP syndrome: Evaluation of 126 cases","volume":"37","author":"Kale","year":"2010","journal-title":"Clin. Exp. Obstet. Gynecol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/IJWH.S168569","article-title":"Incidence, characteristics, maternal complications, and perinatal outcomes associated with preeclampsia with severe features and HELLP syndrome","volume":"10","author":"Kongwattanakul","year":"2018","journal-title":"Int. J. Womens Health"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3349\/ymj.2006.47.3.393","article-title":"Neonatal Outcome after Preterm Delivery in HELLP Syndrome","volume":"47","author":"Kim","year":"2006","journal-title":"Yonsei Med. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1159\/000095665","article-title":"Follow-up analysis of pregnancies complicated by HELLP syndrome","volume":"21","author":"Hupuczi","year":"2006","journal-title":"Fetal Diagn. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.preghy.2016.08.231","article-title":"Long term effects of gestational hypertension and pre-eclampsia on kidney function: Record linkage study","volume":"6","author":"Ayansina","year":"2016","journal-title":"Pregnancy Hypertens."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/10641950802601252","article-title":"Expectant management of severe preeclampsia remote from term: A structured systematic review","volume":"28","author":"Magee","year":"2009","journal-title":"Hypertens. Pregnancy"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"g4731","DOI":"10.1136\/bmj.g4731","article-title":"Hypertensive disorders of pregnancy and the recent increase in obstetric acute renal failure in Canada: Population based retrospective cohort study","volume":"349","author":"Mehrabadi","year":"2014","journal-title":"Br. Med. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/AOG.0000000000001374","article-title":"Investigation of a rise in obstetric acute renal failure in the United States, 1999\u20132011","volume":"127","author":"Mehrabadi","year":"2016","journal-title":"Obstet. Gynecol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/0002-9378(93)90043-I","article-title":"Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome)","volume":"169","author":"Sibai","year":"1993","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9378(16)32330-4","article-title":"Syndrome of hemolysis, elevated liver enzymes, and low platelet count: A severe consequence of hypertension in pregnancy","volume":"142","author":"Weinstein","year":"1982","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2007-04-084533","article-title":"Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome","volume":"111","author":"Fang","year":"2008","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/HYPERTENSIONAHA.113.01420","article-title":"Urinary excretion of C5b-9 in severe preeclampsia: Tipping the balance of complement activation in pregnancy","volume":"62","author":"Burwick","year":"2013","journal-title":"Hypertension"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1182\/blood-2014-07-589366","article-title":"Eculizumab fails to inhibit generation of C5a in vivo","volume":"124","author":"Burwick","year":"2014","journal-title":"Blood"},{"key":"ref_56","unstructured":"Geha, M., Burwick, R.M., and Feinberg, B.B. (2013, January 26\u201329). Eculizumab, a Novel Treatment for Preeclampsia\/HELLP Syndrome. Proceedings of the American Academy of Pediatrics AAP Experience National Conference & Exhibition, Orlando, FL, USA."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1089\/ars.2009.2671","article-title":"Antenatal steroids and antioxidant enzyme activity in preterm infants: Influence of gender and timing","volume":"11","author":"Vento","year":"2009","journal-title":"Antioxid. Redox. Signal."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Turitz, A.L., Too, G.T., and Gyamfi-Bannerman, C. (2016). Proximity of magnesium exposure to delivery and neonatal outcomes. Am. J. Obstet. Gynecol., 215.","DOI":"10.1016\/j.ajog.2016.05.004"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Salmon, J.E., Heuser, C., Triebwasser, M., Liszewski, M.K., Kavanagh, D., Roumenina, L., Branch, D.W., Goodship, T., Fremeaux-Bacchi, V., and Atkinson, J.P. (2011). Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort. PLoS Med., 8.","DOI":"10.1371\/journal.pmed.1001013"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1634\/theoncologist.2008-0086","article-title":"FDA report: Eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Dmytrijuk","year":"2008","journal-title":"Oncologist"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"key":"ref_62","first-page":"1","article-title":"Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria","volume":"5","author":"Sahin","year":"2015","journal-title":"Am. J. Blood Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3324\/haematol.2012.062828","article-title":"Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria","volume":"97","author":"Schrezenmeier","year":"2012","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ejh.12346","article-title":"Paroxysmal nocturnal hemoglobinuria: A single Spanish center\u2019s experience over the last 40 year","volume":"93","author":"Ojeda","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00277-017-3059-x","article-title":"Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: Results of a retrospective analysis from the Spanish PNH Registry","volume":"96","author":"Villegas","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12185-013-1404-y","article-title":"Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial","volume":"98","author":"Kanakura","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2147\/TCRM.S96720","article-title":"Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: Patient selection and special considerations","volume":"12","year":"2016","journal-title":"Ther. Clin. Risk. Manag."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.imbio.2014.11.003","article-title":"Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn","volume":"220","author":"Hallstensen","year":"2015","journal-title":"Immunobiology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","article-title":"A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome","volume":"93","author":"Huerta","year":"2018","journal-title":"Kidney Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40620-016-0357-7","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: Case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J. Nephrol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic Uremic Syndrome in Pregnancy and Postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1681\/ASN.2016090995","article-title":"Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome","volume":"29","author":"Gaggl","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e003573","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40164-017-0064-7","article-title":"Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab","volume":"6","author":"Andries","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000454946","article-title":"Pregnant woman with atypical hemolytic uremic syndrome delivered a healthy newborn under eculizumab treatment","volume":"6","author":"Demir","year":"2016","journal-title":"Case Rep. Nephrol. Dial."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/AOG.0b013e31828e2612","article-title":"Eculizumab for atypical hemolytic uremic syndrome in pregnancy","volume":"122","author":"Ardissino","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40620-018-0517-z","article-title":"Eculizumab in pregnancy: A narrative overview","volume":"32","author":"Sarno","year":"2019","journal-title":"J. Nephrol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/ndt\/gfw314","article-title":"Atypical haemolytic uraemic syndrome and pregnancy: Outcome with ongoing eculizumab","volume":"31","author":"Servais","year":"2016","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Lisonkova, S., Hutcheon, J.A., and Joseph, K.S. (2011). Temporal trends in neonatal outcomes following iatrogenic preterm delivery. BMC Pregnancy Childbirth, 11.","DOI":"10.1186\/1471-2393-11-39"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/AOG.0b013e3181b473fc","article-title":"Heterogeneity of preterm birth subtypes in relation to neonatal death","volume":"114","author":"Chen","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajog.2017.04.032","article-title":"Short-term costs of preeclampsia to the United States health care system","volume":"217","author":"Stevens","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_88","first-page":"103","article-title":"Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Preterm neonatal morbidity and mortality by gestational age: A contemporary cohort","volume":"215","author":"Manuck","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archpediatrics.2010.99","article-title":"Performance, Effectiveness, and Cost of Treatment Episodes (PERFECT) Preterm Infant Study Group. Hospital costs and quality of life during 4 years after very preterm birth","volume":"164","author":"Korvenranta","year":"2010","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.trsl.2011.10.004","article-title":"Prematurity in mice leads to reduction in nephron number, hypertension, and proteinuria","volume":"159","author":"Stelloh","year":"2012","journal-title":"Transl. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.blre.2017.02.003","article-title":"Complementopathies","volume":"31","author":"Baines","year":"2017","journal-title":"Blood Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood-2015-06-640995","article-title":"Complement in hemolytic anemia","volume":"126","author":"Brodsky","year":"2015","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.molimm.2017.05.013","article-title":"Complement in clinical medicine: Clinical trials, case reports and therapy monitoring","volume":"89","author":"Ricklin","year":"2017","journal-title":"Mol. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ndt\/gfw353","article-title":"Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome","volume":"32","author":"Verhave","year":"2017","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/0272989X14539731","article-title":"Opportunity cost of funding drugs for rare diseases: The cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"34","author":"Coyle","year":"2014","journal-title":"Med. Decis. Mak."},{"key":"ref_98","unstructured":"Europan Medicines Agency (2019, February 16). Soliris, Summary of Product Characteristics, Annex I. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: Recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kumar, D., King, M., Jim, B., and Acharya, A. (2019). Recurrent case of pregnancy-induced atypical haemolytic uremic syndrome (P-aHUS). BMJ Case Rep., 17.","DOI":"10.1136\/bcr-2018-226571"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00281-017-0645-x","article-title":"Complement activation, a threat to pregnancy","volume":"40","author":"Girardi","year":"2018","journal-title":"Semin Immunopathol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.kint.2016.04.018","article-title":"Targeting the complement cascade: Novel treatments coming down the pike","volume":"90","author":"Thurman","year":"2016","journal-title":"Kidney Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/3\/407\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:40:18Z","timestamp":1760186418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/3\/407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,24]]},"references-count":102,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["jcm8030407"],"URL":"https:\/\/doi.org\/10.3390\/jcm8030407","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,24]]}}}